IOSP vs. BCPC, ASH, HUN, NGVT, HWKN, LOOP, GURE, OLN, FMC, and CALM
Should you be buying Innospec stock or one of its competitors? The main competitors of Innospec include Balchem (BCPC), Ashland (ASH), Huntsman (HUN), Ingevity (NGVT), Hawkins (HWKN), Loop Industries (LOOP), Gulf Resources (GURE), Olin (OLN), FMC (FMC), and Cal-Maine Foods (CALM).
Innospec (NASDAQ:IOSP) and Balchem (NASDAQ:BCPC) are both mid-cap basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.
Innospec has higher revenue and earnings than Balchem. Innospec is trading at a lower price-to-earnings ratio than Balchem, indicating that it is currently the more affordable of the two stocks.
Innospec has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Balchem has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.
96.6% of Innospec shares are owned by institutional investors. Comparatively, 87.9% of Balchem shares are owned by institutional investors. 1.5% of Innospec shares are owned by company insiders. Comparatively, 1.8% of Balchem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Balchem has a net margin of 11.77% compared to Innospec's net margin of 7.14%. Innospec's return on equity of 13.69% beat Balchem's return on equity.
Innospec pays an annual dividend of $1.44 per share and has a dividend yield of 1.2%. Balchem pays an annual dividend of $0.79 per share and has a dividend yield of 0.6%. Innospec pays out 25.9% of its earnings in the form of a dividend. Balchem pays out 23.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Balchem has a consensus price target of $135.00, suggesting a potential downside of 3.06%. Given Balchem's higher possible upside, analysts clearly believe Balchem is more favorable than Innospec.
In the previous week, Balchem had 6 more articles in the media than Innospec. MarketBeat recorded 8 mentions for Balchem and 2 mentions for Innospec. Innospec's average media sentiment score of 1.28 beat Balchem's score of 0.08 indicating that Innospec is being referred to more favorably in the media.
Balchem received 57 more outperform votes than Innospec when rated by MarketBeat users. Likewise, 66.67% of users gave Balchem an outperform vote while only 65.79% of users gave Innospec an outperform vote.
Summary
Balchem beats Innospec on 10 of the 19 factors compared between the two stocks.
Get Innospec News Delivered to You Automatically
Sign up to receive the latest news and ratings for IOSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IOSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innospec Competitors List
Related Companies and Tools
